Physician profile
Carly Roman
NPI 1629416433
$35,980.54
in general payments reported to CMS, 2019-2025
18 companies · $942 in 2025
The $942 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $21K · 2021: $9,891 · 2022: $2,162 · 2023: $288 · 2024: $767 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.90 |
| Education | $122.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $33,092.41 | 2019-2025 | Nemluvio, Aklief |
| Abbvie INC. | $1,268.02 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $413.33 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $176.11 | 2024-2025 | Zoryve |
| Allergan, INC. | $134.28 | 2019 | |
| Incyte Corporation | $120.73 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $112.53 | 2021-2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $112.47 | 2019-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $105.02 | 2021 | |
| Leo Pharma INC. | $96.00 | 2022-2024 | Adbry |
| Revance Therapeutics, INC. | $73.39 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $55.19 | 2023-2025 | |
| Dermavant Sciences, INC. | $51.04 | 2023-2024 | Vtama |
| Ucb, INC. | $49.20 | 2025 | Bimzelx |
| Pfizer INC. | $44.61 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.34 | 2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $28.29 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $16.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.